Gaps and uncertainties in existing international guidelines include the following: Baseline regimens where intensification approaches were not supported by strong evidence Guidelines did not specify how dose intensification should be operationalised. A lack of any clear published guidance in this area probably also explains the large variability in yellow zone instructions across existing AAPs. [The yellow zone describes loss of control and corresponding instrictions for the therapeutic intensification].